28 Jul Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases Posted at 10:00h in News Share ... Read More
31 Mar Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances Posted at 08:00h in News Share Read More
10 Mar Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets Posted at 15:00h in News Share Read More
07 Oct Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody™ therapeutics Posted at 07:00h in News Share Read More
08 May Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies at BioEquity Europe 2019 Posted at 08:00h in Events Share Read More
12 Nov Complix to Present its Cell Penetrating Alphabodies Acting on Important Intracellular Targets at PEGS Europe 2018 Posted at 08:00h in Events Share Read More
09 May Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies Acting on Intracellular Cancer Targets at BioEquity Europe 2018 Posted at 08:00h in Events Share Read More
14 Dec Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies™ against intracellular cancer targets Posted at 09:00h in News Share Read More
31 Oct Complix to Present its Cell Penetrating Alphabody™ Platform Acting on Important Intracellular Targets at PEGS Europe 2017 Posted at 09:00h in Events Share Read More
